Centre for Advance Research, Faculty of Medicine, King George's Medical University, Lucknow, India.
Department of Biosciences Manipal University Jaipur, Dehmi Kalan, Jaipur-Ajmer Expressway, Jaipur, Rajasthan, India.
Asian Pac J Cancer Prev. 2024 Sep 1;25(9):3187-3197. doi: 10.31557/APJCP.2024.25.9.3187.
Triple negative breast cancer (TNBC) is an aggressive from of breast cancer and is associated with poor prognosis. Tumor microenvironment of breast cancer consists of a wide range of cell types, including tumor-infiltrating lymphocytes (TILs). Accumulating evidence indicate that TILs play a crucial role in cancer progression and resistance to standard chemotherapy.
We used online computational tools to evaluate the prognostic significance of CD247 and CD4 in TNBC.
TNBC patients with lower expression of CD247 and CD4 have much shorter relapse- free survival and overall survival than the patients with higher expression of these genes. CD247 and CD4 expression show a strong positive correlation with tumor-infiltrating dendritic cells, B-cells, CD4+, CD8+, and neutrophils.
We've concluded that low levels of CD247 and CD4 may stop immune cells from entering the area around the tumor, which stops cancer cells from being killed and gives the patient a bad outlook. These findings suggest that CD247 and CD4 may be useful biomarkers or as a target to understand the progression of TNBC. Our findings also suggest that CD247 and CD4 targeted therapeutics should be explored in detail, and could be a potentially used as atreatment strategy for TNBC.
三阴性乳腺癌（TNBC）是一种侵袭性乳腺癌，预后不良。乳腺癌的肿瘤微环境包含多种细胞类型，包括肿瘤浸润淋巴细胞（TILs）。越来越多的证据表明，TILs 在癌症进展和对标准化疗的耐药性中发挥着关键作用。
我们使用在线计算工具来评估 CD247 和 CD4 在 TNBC 中的预后意义。
与 CD247 和 CD4 高表达的患者相比，TNBC 患者中 CD247 和 CD4 表达水平较低的患者无复发生存期和总生存期明显更短。CD247 和 CD4 的表达与肿瘤浸润树突状细胞、B 细胞、CD4+、CD8+和中性粒细胞呈强正相关。
我们得出结论，CD247 和 CD4 水平较低可能阻止免疫细胞进入肿瘤周围区域，从而阻止癌细胞被杀死，并使患者预后不良。这些发现表明 CD247 和 CD4 可能是有用的生物标志物或作为理解 TNBC 进展的靶点。我们的研究结果还表明，应详细探索针对 CD247 和 CD4 的靶向治疗药物，并可能作为 TNBC 的潜在治疗策略。
